GILDGilead SciencesRunning, no new patients
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
Head and Neck Squamous Cell Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 39 (final count)
- Started
- Feb 18, 2025
- Main results expected
- Mar 2027
- Fully finished
- Mar 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective response rate (ORR)
Measured over: Up to 36 months
Progression-free survival (PFS)
Measured over: Up to 36 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06727565 · record last updated 2026-09-03 · checked 2026-11-09 15:47 UTC